528 related articles for article (PubMed ID: 21072210)
21. A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines through activation of aryl hydrocarbon receptor.
Fukasawa K; Kagaya S; Maruyama S; Kuroiwa S; Masuda K; Kameyama Y; Satoh Y; Akatsu Y; Tomura A; Nishikawa K; Horie S; Ichikawa Y
Mol Cancer Ther; 2015 Feb; 14(2):343-54. PubMed ID: 25522763
[TBL] [Abstract][Full Text] [Related]
22. Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy.
Al-Dhfyan A; Alaiya A; Al-Mohanna F; Attwa MW; AlAsmari AF; Bakheet SA; Korashy HM
J Adv Res; 2023 Aug; 50():177-192. PubMed ID: 36307019
[TBL] [Abstract][Full Text] [Related]
23. Hexachlorobenzene modulates the crosstalk between the aryl hydrocarbon receptor and transforming growth factor-β1 signaling, enhancing human breast cancer cell migration and invasion.
Miret N; Pontillo C; Ventura C; Carozzo A; Chiappini F; Kleiman de Pisarev D; Fernández N; Cocca C; Randi A
Toxicology; 2016 Jul; 366-367():20-31. PubMed ID: 27519288
[TBL] [Abstract][Full Text] [Related]
24. Effect of dioxin and 17β-estradiol on the expression of cytochrome P450 1A1 gene via an estrogen receptor dependent pathway in cellular and xenografted models.
Go RE; Hwang KA; Kim CW; Byun YS; Nam KH; Choi KC
Environ Toxicol; 2017 Oct; 32(10):2225-2233. PubMed ID: 28618207
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
26. Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.
Zhang S; Kim K; Jin UH; Pfent C; Cao H; Amendt B; Liu X; Wilson-Robles H; Safe S
Mol Cancer Ther; 2012 Jan; 11(1):108-18. PubMed ID: 22034498
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor subtype- and promoter-specific modulation of aryl hydrocarbon receptor-dependent transcription.
Wihlén B; Ahmed S; Inzunza J; Matthews J
Mol Cancer Res; 2009 Jun; 7(6):977-86. PubMed ID: 19470599
[TBL] [Abstract][Full Text] [Related]
28. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Loaiza-Pérez AI; Kenney S; Boswell J; Hollingshead M; Alley MC; Hose C; Ciolino HP; Yeh GC; Trepel JB; Vistica DT; Sausville EA
Mol Cancer Ther; 2004 Jun; 3(6):715-25. PubMed ID: 15210858
[TBL] [Abstract][Full Text] [Related]
29. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation.
Hall JM; Barhoover MA; Kazmin D; McDonnell DP; Greenlee WF; Thomas RS
Mol Endocrinol; 2010 Feb; 24(2):359-69. PubMed ID: 20032195
[TBL] [Abstract][Full Text] [Related]
30. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
Farnie G; Sotgia F; Lisanti MP
Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
[TBL] [Abstract][Full Text] [Related]
31. Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer.
Wang T; Wyrick KL; Meadows GG; Wills TB; Vorderstrasse BA
Toxicol Sci; 2011 Dec; 124(2):291-8. PubMed ID: 21948867
[TBL] [Abstract][Full Text] [Related]
32. A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation.
Jafari SM; Joshaghani HR; Panjehpour M; Aghaei M
Cell Oncol (Dordr); 2018 Feb; 41(1):61-72. PubMed ID: 29218545
[TBL] [Abstract][Full Text] [Related]
33. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15.
Azzi S; Bruno S; Giron-Michel J; Clay D; Devocelle A; Croce M; Ferrini S; Chouaib S; Vazquez A; Charpentier B; Camussi G; Azzarone B; Eid P
J Natl Cancer Inst; 2011 Dec; 103(24):1884-98. PubMed ID: 22043039
[TBL] [Abstract][Full Text] [Related]
34. Activation of aryl hydrocarbon receptor (ahr) by tranilast, an anti-allergy drug, promotes miR-302 expression and cell reprogramming.
Hu W; Zhao J; Pei G
J Biol Chem; 2013 Aug; 288(32):22972-84. PubMed ID: 23821545
[TBL] [Abstract][Full Text] [Related]
35. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially.
Ciolino HP; Daschner PJ; Yeh GC
Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):715-22. PubMed ID: 10359656
[TBL] [Abstract][Full Text] [Related]
36. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
Front Immunol; 2021; 12():791551. PubMed ID: 35046949
[TBL] [Abstract][Full Text] [Related]
37. Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status.
Angus WG; Larsen MC; Jefcoate CR
Carcinogenesis; 1999 Jun; 20(6):947-55. PubMed ID: 10357772
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronic acid hydrogels with defined crosslink density for the efficient enrichment of breast cancer stem cells.
Tan S; Yamashita A; Gao SJ; Kurisawa M
Acta Biomater; 2019 Aug; 94():320-329. PubMed ID: 31125725
[TBL] [Abstract][Full Text] [Related]
39. Effects of human blood levels of two PAH mixtures on the AHR signalling activation pathway and CYP1A1 and COMT target genes in granulosa non-tumor and granulosa tumor cell lines.
Zajda K; Ptak A; Rak A; Fiedor E; Grochowalski A; Milewicz T; Gregoraszczuk EL
Toxicology; 2017 Aug; 389():1-12. PubMed ID: 28710019
[TBL] [Abstract][Full Text] [Related]
40. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
